The association of lipid levels with mortality in patients on chronic peritoneal dialysis

被引:65
作者
Habib, Arsalan N.
Baird, Bradley C.
Leypoldt, John K.
Cheung, Alfred K.
Goldfarb-Rumyantzev, Alexander S.
机构
[1] Univ Utah, Sch Med, Dialysis Program, Div Nephrol & Hypertens, Salt Lake City, UT 84132 USA
[2] Vet Affairs Salt Lake City Healthcare, Salt Lake City, UT USA
关键词
cholesterol; lipids; mortality; peritoneal dialysis; triglycerides;
D O I
10.1093/ndt/gfl272
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. The role of traditional risk factors, including plasma lipids, in the pathogenesis of cardiovascular (CV) disease in chronic dialysis patients is unclear. Previous studies have suggested that lower serum total cholesterol (TC) is associated with higher mortality in patients on chronic haemodialysis (HD). Whether this relationship is specific to the HD population or is common to the uraemic state is unclear. The present study evaluated the association of serum TC and triglycerides with clinical outcomes in chronic peritoneal dialysis (PD) patients. Methods. Data of 1053 PD patients from the United States Renal Data System (USRDS) prospective Dialysis Morbidity and Mortality Study Wave 2 were examined. Cox regression was used to evaluate the relationship between lipid levels and mortality. Results. Patients with TC levels <= 125 mg/dl (3.24 mmol/l) had a statistically significant increased risk of an all-cause mortality, including those taking or not taking lipid-modifying medications, compared with the reference of 176-225 mg/dl (4.54-5.83 mmol/l). In stratified analysis, this association was demonstrated in patients with serum albumin > 3.0 g/dl (30 g/l), but not with albumin <= 3.0 g/dl. Compared with patients with triglyceride levels of 201-300 mg/dl (2.27-3.39 mmol/l), a statistically significant reduction of all-cause, but not CV, mortality was observed in patients with triglyceride levels of 101-200 mg/dl (1.14-2.26 mmol/l), as well as in the subgroup with serum albumin levels < 3.0 g/dl (30 g/l) and triglycerides of <= 100 mg/dl (1.13 mmol/l) and 101-200 mg/dl (1.14-2.26 mmol/l). Conclusions. While confounding factors and causal pathways have not been clearly identified, aggressive lowering of plasma cholesterol in PD patients is not supported by this study, however, treatment of hypertriglyceridaemia may be warranted with triglyceride levels > 200 mg/dl (2.26 mmol/l).
引用
收藏
页码:2881 / 2892
页数:12
相关论文
共 35 条
[1]  
Austin MA, 1999, AM J CARDIOL, V83, p13F
[2]   Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study [J].
Austin, MA ;
McKnight, B ;
Edwards, KL ;
Bradley, CM ;
McNeely, MJ ;
Psaty, BM ;
Brunzell, JD ;
Motulsky, AC .
CIRCULATION, 2000, 101 (24) :2777-2782
[3]   THE UREMIC DYSLIPIDEMIA - A CROSS-SECTIONAL AND LONGITUDINAL-STUDY [J].
AVRAM, MM ;
GOLDWASSER, P ;
BURRELL, DE ;
ANTIGNANI, A ;
FEIN, PA ;
MITTMAN, N .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1992, 20 (04) :324-335
[4]  
Coresh J, 1998, J Am Soc Nephrol, V9, pS24
[5]  
CRESSMAN MD, 1993, MINER ELECTROL METAB, V19, P180
[6]  
Dupont WD., 2002, STAT MODELING BIOMED
[7]   Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease [J].
Eberly, LE ;
Stamler, J ;
Neaton, JD .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (09) :1077-+
[8]  
Fleischmann EH, 2001, CLIN NEPHROL, V56, P221
[9]   Clinical epidemiology of cardiovascular disease in chronic renal disease [J].
Foley, RN ;
Parfrey, PS ;
Sarnak, MJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (05) :S112-S119
[10]  
Fox CS, 2004, CLIN NEPHROL, V61, P299